Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 28;22(2):811. doi: 10.3892/etm.2021.10243

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Li et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

NRG pretreatment attenuates cardiac I/R injury. Serum levels of (A) CK-MB, (B) cTnI and (C) LDH (n=5) after I/R and following pretreatment with different NRG doses. The expression levels of (D) CK-MB, (E) cTnI and (F) LDH (n=5) after I/R with use of a PI3K/Akt inhibitor. (G) Representative images of heart tissues following hematoxylin and eosin staining. (H) Damage score (n=5). NRG, naringin; I/R, ischemia reperfusion; CK-MB, creatine kinase myocardial band; cTn1, cardiac troponin 1; LDH, lactate dehydrogenase; LY, PI3K/Akt inhibitor LY294002; NRG25, 25 mg/kg naringin; NRG50, 50 mg/kg naringin; NRG100, 100 mg/kg naringin. ^aP<0.05 vs. sham group; ^bP<0.05 vs. I/R group; ^cP<0.05 vs. I/R group; ^dP<0.05 vs. NRG50 + I/R group.